SCHEMBL30206083

SCHEMBL30206083

Cn1cnc2c(-c3nc(C(N)=O)c(Nc4ccc(N5CCOCC5)cc4)nc3N)cccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EML4 Q9HC35 5/20 0.46
▸ ALK Q9UM73 5/20 0.46
▸ RET P07949 4/20 0.43
▸ ROS1 P08922 4/20 0.43
▸ FLT3 P36888 4/20 0.43
▸ CCNA2 P20248 3/20 0.43
▸ CDK2 P24941 3/20 0.43
▸ CDK4 P11802 2/20 0.43
▸ CCND3 P30281 2/20 0.43
▸ CDK6 Q00534 2/20 0.43
▸ AURKA O14965 1/20 0.43
▸ CCNA1 P78396 1/20 0.41
▸ MAPK8 P45983 1/20 0.40
▸ MAPK9 P45984 1/20 0.40
▸ MAPK10 P53779 1/20 0.40
▸ STAT6 P42226 5/20 0.40
▸ SYK P43405 2/20 0.40
▸ MAPKAPK5 Q8IW41 1/20 0.40
▸ BTK Q06187 1/20 0.39
▸ LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24943804 1.00 EML4 (0.46) EML4ALKRETROS1FLT3
SCHEMBL24944946 0.92 EML4 (0.46) EML4ALKRETROS1FLT3
SCHEMBL30205573 0.92 EML4 (0.46) EML4ALKRETROS1FLT3
SCHEMBL24944396 0.92 EML4 (0.46) EML4ALKRETROS1FLT3
SCHEMBL24944369 0.91 EML4 (0.49) EML4ALKRETROS1FLT3
SCHEMBL24944953 0.90 EML4 (0.47) EML4ALKRETROS1FLT3
SCHEMBL24944747 0.90 EML4 (0.46) EML4ALKRETROS1FLT3
SCHEMBL24944375 0.90 EML4 (0.44) EML4ALKRETROS1FLT3
SCHEMBL24944398 0.90 EML4 (0.45) EML4ALKRETROS1FLT3
SCHEMBL30206126 0.90 EML4 (0.44) EML4ALKRETROS1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 EML4 2189/4885ALK 2002/4885RET 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback